- Statistically significant 68% (p
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
Apellis Pharmaceuticals, Inc. on 6ix
Earlier from Apellis Pharmaceuticals
- Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
- Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
- Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
- Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
- Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
Later from Apellis Pharmaceuticals
- Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
- Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
- Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Apellis Announces Keli Walbert to Join the Board of Directors
- Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference
Follow Apellis Pharmaceuticals into a list and get an email when it puts out news.
Follow Apellis Pharmaceuticals